190 related articles for article (PubMed ID: 33616089)
1. Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo.
Volckmar J; Knop L; Hirsch T; Frentzel S; Erck C; van Ham M; Stegemann-Koniszewski S; Bruder D
J Vis Exp; 2021 Feb; (168):. PubMed ID: 33616089
[TBL] [Abstract][Full Text] [Related]
2. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
[TBL] [Abstract][Full Text] [Related]
3. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
4. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity.
Kreutz M; Giquel B; Hu Q; Abuknesha R; Uematsu S; Akira S; Nestle FO; Diebold SS
PLoS One; 2012; 7(7):e40208. PubMed ID: 22808118
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
7. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice.
Stylianou E; Pepponi I; van Dolleweerd CJ; Paul MJ; Ma JK; Reljic R
Vaccine; 2011 Mar; 29(12):2279-86. PubMed ID: 21272603
[TBL] [Abstract][Full Text] [Related]
8. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
[TBL] [Abstract][Full Text] [Related]
9. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.
Tenbusch M; Nchinda G; Storcksdieck genannt Bonsmann M; Temchura V; Überla K
Int Immunol; 2013 Apr; 25(4):247-58. PubMed ID: 23184617
[TBL] [Abstract][Full Text] [Related]
10. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
[TBL] [Abstract][Full Text] [Related]
11. DEC-205 receptor-mediated long-circling nanoliposome as an antigen and
Feng H; Yang X; Fan J; Zhang L; Liu Q; Chai D
Drug Deliv; 2020 Dec; 27(1):1581-1596. PubMed ID: 33169636
[TBL] [Abstract][Full Text] [Related]
12. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
[TBL] [Abstract][Full Text] [Related]
13. Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.
Volckmar J; Gereke M; Ebensen T; Riese P; Philipsen L; Lienenklaus S; Wohlleber D; Klopfleisch R; Stegemann-Koniszewski S; Müller AJ; Gruber AD; Knolle P; Guzman CA; Bruder D
Sci Rep; 2017 Mar; 7():43985. PubMed ID: 28266658
[TBL] [Abstract][Full Text] [Related]
14. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
15. Induction of innate and adaptive immunity by delivery of poly dA:dT to dendritic cells.
Barbuto S; Idoyaga J; Vila-Perelló M; Longhi MP; Breton G; Steinman RM; Muir TW
Nat Chem Biol; 2013 Apr; 9(4):250-6. PubMed ID: 23416331
[TBL] [Abstract][Full Text] [Related]
16. Targeting DEC-205
Tabansky I; Keskin DB; Watts D; Petzold C; Funaro M; Sands W; Wright P; Yunis EJ; Najjar S; Diamond B; Cao Y; Mooney D; Kretschmer K; Stern JNH
Mol Med; 2018 May; 24(1):17. PubMed ID: 30134798
[TBL] [Abstract][Full Text] [Related]
17. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells.
Do Y; Park CG; Kang YS; Park SH; Lynch RM; Lee H; Powell BS; Steinman RM
Eur J Immunol; 2008 Jan; 38(1):20-9. PubMed ID: 18081041
[TBL] [Abstract][Full Text] [Related]
18. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
Bozzacco L; Trumpfheller C; Huang Y; Longhi MP; Shimeliovich I; Schauer JD; Park CG; Steinman RM
Eur J Immunol; 2010 Jan; 40(1):36-46. PubMed ID: 19830741
[TBL] [Abstract][Full Text] [Related]
19. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
[TBL] [Abstract][Full Text] [Related]
20. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
